Plant Comparison
Rosemary vs Chasteberry
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Rosemary and Chasteberry: both belong to the Lamiaceae family; they share 1 indicated use (menstrual cramps).
Evidence face-off — shared uses
| Condition | Rosemary | Chasteberry | Verdict |
|---|---|---|---|
| Menstrual cramps | 3/10 | 8/10 | Stronger for Chasteberry |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
The volatile oil, dominated by 1,8-cineole and camphor, gives the characteristic aroma and much of the antimicrobial activity.
Potent antioxidant diterpenes considered largely responsible for rosemary's strong preservative and antioxidant activity.
Bind dopamine D2 receptors in the pituitary, reducing prolactin release - the key mechanism.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from neuroprotective action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from antispasmodic action
inferred from antispasmodic action
inferred from anti-inflammatory action
Eases cyclical breast pain (mastalgia) and menstrual-cycle complaints including cramping. The proposed mechanism is dopaminergic suppression of latent hyperprolactinaemia.
Safety, Cautions & Contraindications
Culinary use is entirely safe. Essential oil should not be ingested in large amounts; avoid during pregnancy in medicinal doses. May trigger epileptic seizures in predisposed individuals at high doses. May interact with anticoagulants and antiplatelet drugs.
Duke (2002) does not appear to include a dedicated entry for rosemary (Salvia rosmarinus / Rosmarinus officinalis) as a primary herb entry in the section searched; however, rosemary is referenced throughout the text in relation to antioxidant and antimicrobial properties of its key compounds (carnosol, rosmarinic acid). Commission E (KOM) approves rosemary for dyspeptic complaints and externally for rheumatic conditions and circulatory problems.
Reported adverse events are mild and reversible (nausea, headache, gastrointestinal upset, menstrual changes, acne, itching or rash).
Because it acts on dopamine and the hormonal axis, avoid alongside dopamine-antagonist (antipsychotic) or dopamine-agonist drugs and use caution with hormonal medicines (oral contraceptives, HRT) and hormone-sensitive conditions.
Avoid during pregnancy and breastfeeding. A systematic review found only poor-grade evidence (theoretical, expert opinion and in vitro) suggesting oestrogenic, progesteronic, uterine-stimulant and emmenagogue activity, and expert opinion actively conflicts on whether chastetree increases or decreases lactation. The precaution rests on absence of safety data rather than on demonstrated harm.
External Ids
Botanical Description
Evergreen, woody shrub (Lamiaceae), 1-2 m tall, with dense, needle-like, dark green, aromatic leaves, white-felted beneath. Small, pale blue to violet, two-lipped flowers are borne in the leaf axils.[1]
Deciduous shrub or small tree with slender, aromatic, palmately compound leaves of narrow, lance-shaped leaflets, greyish-downy beneath. Small, fragrant, lilac to violet flowers are borne in long, slender terminal spikes, followed by small, dark, peppercorn-like berries with a peppery, aromatic taste.[1]
Habitat
Native to the Mediterranean coast, growing on dry, rocky, sunny slopes and coastal scrub; widely cultivated as a culinary and medicinal herb worldwide, tolerating poor, well-drained soils and drought.[1]
Native to the Mediterranean region and Central Asia, growing along riverbanks, streamsides and coastal scrub; widely cultivated in warm-temperate climates worldwide.[1]
Harvesting
Leafy sprigs are cut throughout the year (the plant is evergreen), though essential-oil content is often considered highest just before or during flowering; leaves are stripped from the stem and dried, or used fresh.[1]
The ripe berries are collected in autumn once they have darkened and dried, then further dried and stored for use in decoctions or standardised extracts.
Traditional Uses
Rosemary has an ancient Mediterranean reputation as a memory and circulation tonic ('rosemary for remembrance'), a digestive carminative, and an antiseptic for minor wounds. Commission E approves it for dyspeptic complaints internally and for rheumatic conditions and circulatory problems externally; modern research on rosmarinic acid and carnosic acid supports antioxidant, anti-inflammatory, antimicrobial and cognitive-supportive activity.[1]
Chasteberry has a long Mediterranean tradition, reflected in its 'chaste tree' name, historically used to reduce libido in monastic settings, and, more centrally to its modern use, as a traditional women's tonic for menstrual irregularities, premenstrual complaints and cyclical breast tenderness; standardised extracts are now among the best-clinically-studied herbal remedies for premenstrual syndrome, acting via dopaminergic modulation of prolactin.[1]
Preparations
Dried fruit extract standardised to agnuside/casticin content, taken as tablets or capsules; the form used in most clinical PMS and cyclical breast pain trials.
Dosage
Commission E approves rosemary for dyspeptic complaints (internal use) and, externally, for rheumatic conditions and circulatory problems; typical internal use is roughly 2-4 g dried leaf as tea, up to three times daily. Educational reference only, not a prescription; avoid concentrated essential oil internally and in pregnancy/epilepsy.
Clinical trials for PMS commonly use extracts providing around 20-40 mg of dried fruit extract daily, taken over several menstrual cycles for full effect. Educational reference only, not a prescription.
References
Lookalikes Review
References & Sources
- de Oliveira, J.R., Camargo, S.E.A. and de Oliveira, L.D (2019) 'Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent', Journal of Biomedical Science, 26(1), pp. 5. doi:10.1186/s12929-019-0499-8 Meta-analysis / review
https://doi.org/10.1186/s12929-019-0499-8 - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2025) 'Toxicity and safety of rosemary (Rosmarinus officinalis): a comprehensive review', Naunyn-Schmiedeberg's Archives of Pharmacology, 398(1), pp. 9-23. doi:10.1007/s00210-024-03336-9 Meta-analysis / review
https://doi.org/10.1007/s00210-024-03336-9 - Zhang, L. and Lu, J (2024) 'Rosemary (Rosmarinus officinalis L.) polyphenols and inflammatory bowel diseases: Major phytochemicals, functional properties, and health effects', Fitoterapia, 177, pp. 106074. doi:10.1016/j.fitote.2024.106074 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2024.106074 - Ahmed, H.M. and Babakir-Mina, M (2020) 'Investigation of rosemary herbal extracts (Rosmarinus officinalis) and their potential effects on immunity', Phytotherapy Research, 34(8), pp. 1829-1837. doi:10.1002/ptr.6648 Preclinical
https://doi.org/10.1002/ptr.6648 - Li, T., Wang, W., Guo, Q., Li, J. and others (2023) 'Rosemary (Rosmarinus officinalis L.) hydrosol based on serotonergic synapse for insomnia', Journal of Ethnopharmacology, 318(Pt B), pp. 116984. doi:10.1016/j.jep.2023.116984 Preclinical
https://doi.org/10.1016/j.jep.2023.116984 - Hassani, F.V., Shirani, K. and Hosseinzadeh, H (2016) 'Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review', Naunyn-Schmiedeberg's Archives of Pharmacology, 389(9), pp. 931-949. doi:10.1007/s00210-016-1256-0 Meta-analysis / review
https://doi.org/10.1007/s00210-016-1256-0 - Gonzalez-Vallinas, M., Reglero, G. and Ramirez de Molina, A (2015) 'Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy', Nutrition and Cancer, 67(8), pp. 1221-1229. doi:10.1080/01635581.2015.1082110 Meta-analysis / review
https://doi.org/10.1080/01635581.2015.1082110 - Hussain, S.M., Syeda, A.F., Alshammari, M., Alnasser, S. and others (2022) 'Cognition enhancing effect of rosemary (Rosmarinus officinalis L.) in lab animal studies: a systematic review and meta-analysis', Brazilian Journal of Medical and Biological Research, 55, pp. e11593. doi:10.1590/1414-431X2021e11593 Meta-analysis / review
https://doi.org/10.1590/1414-431X2021e11593 - Nematolahi, P., Mehrabani, M., Karami-Mohajeri, S. and Dabaghzadeh, F (2018) 'Effects of Rosmarinus officinalis L. on memory performance, anxiety, depression, and sleep quality in university students: A randomized clinical trial', Complementary Therapies in Clinical Practice, 30, pp. 24-28. doi:10.1016/j.ctcp.2017.11.004 Randomized trial
https://doi.org/10.1016/j.ctcp.2017.11.004 - Ulbricht, C., Abrams, T.R., Brigham, A., Ceurvels, J. and others (2010) 'An evidence-based systematic review of rosemary (Rosmarinus officinalis) by the Natural Standard Research Collaboration', Journal of Dietary Supplements, 7(4), pp. 351-413. doi:10.3109/19390211.2010.525049 Meta-analysis / review
https://doi.org/10.3109/19390211.2010.525049 - Hoffmann, D (2003) 'Medical Herbalism'. Traditional / reference
https://scholar.google.com/scholar?q=Medical%20Herbalism - Moss, M., Cook, J., Wesnes, K. and Duckett, P (2003) 'Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults', 113(1), pp. 15--38. doi:10.1080/00207450390161903 Clinical study
https://doi.org/10.1080/00207450390161903 - Petersen, M. and Simmonds, M.S.J (2003) 'Rosmarinic acid', 62(2), pp. 121--125. Traditional / reference
https://scholar.google.com/scholar?q=Rosmarinic%20acid - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
- van Die, M.D., Burger, H.G., Teede, H.J. and Bone, K.M (2012) 'Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials', Planta Medica. doi:10.1055/s-0032-1327831 Meta-analysis / review
https://doi.org/10.1055/s-0032-1327831 - Csupor, D., Lantos, T., Hegyi, P., Benko, R. and others (2019) 'Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials', Complementary Therapies in Medicine, 47, pp. 102190. doi:10.1016/j.ctim.2019.08.024 Meta-analysis / review
https://doi.org/10.1016/j.ctim.2019.08.024 - Verkaik, S., Kamperman, A.M., van Westrhenen, R. and Schulte, P.F.J (2017) 'The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis', American Journal of Obstetrics and Gynecology, 217(2), pp. 150-166. doi:10.1016/j.ajog.2017.02.028 Meta-analysis / review
https://doi.org/10.1016/j.ajog.2017.02.028 - Ooi, S.L., Watts, S., McClean, R. and Pak, S.C (2020) 'Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis', Journal of Women's Health, 29(2), pp. 262-278. doi:10.1089/jwh.2019.7770 Meta-analysis / review
https://doi.org/10.1089/jwh.2019.7770 - Holler, M., Steindl, H., Abramov-Sommariva, D., Kleemann, J. and others (2024) 'Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study', Archives of Gynecology and Obstetrics, 309(5), pp. 2089-2098. doi:10.1007/s00404-023-07363-4 Clinical study
https://doi.org/10.1007/s00404-023-07363-4 - Cerqueira, R.O., Frey, B.N., Leclerc, E. and Brietzke, E (2017) 'Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review', Archives of Women's Mental Health, 20(6), pp. 713-719. doi:10.1007/s00737-017-0791-0 Meta-analysis / review
https://doi.org/10.1007/s00737-017-0791-0 - van Die, M.D., Burger, H.G., Teede, H.J. and Bone, K.M (2009) 'Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of menopause-related complaints', Journal of Alternative and Complementary Medicine, 15(8), pp. 853-862. doi:10.1089/acm.2008.0447 Meta-analysis / review
https://doi.org/10.1089/acm.2008.0447 - Daniele, C., Thompson Coon, J., Pittler, M.H. and Ernst, E (2005) 'Vitex agnus castus: a systematic review of adverse events', Drug Safety. doi:10.2165/00002018-200528040-00004 Meta-analysis / review
https://doi.org/10.2165/00002018-200528040-00004 - Wuttke, W., Jarry, H., Christoffel, V., Spengler, B. and Seidlova-Wuttke, D (2003) 'Chaste tree (Vitex agnus-castus) - pharmacology and clinical indications', Phytomedicine, 10(4), pp. 348-357. doi:10.1078/094471103322004866 Meta-analysis / review
https://doi.org/10.1078/094471103322004866 - Kuruzum-Uz, A., Stroch, K., Demirezer, L.O. and Zeeck, A (2003) 'Glucosides from Vitex agnus-castus', Phytochemistry, 63(8), pp. 959-964. doi:10.1016/s0031-9422(03)00285-1 Preclinical
https://doi.org/10.1016/s0031-9422(03)00285-1 - Rani, A. and Sharma, A (2013) 'The genus Vitex: A review', Pharmacognosy Reviews, 7(14), pp. 188-198. doi:10.4103/0973-7847.120522 Traditional / reference
https://doi.org/10.4103/0973-7847.120522 - Mollazadeh, S. and Mirghafourvand, M. and Abdollahi, N. G (2019) 'The effects of Vitex agnus-castus on menstrual bleeding: a systematic review and meta-analysis', Journal of Complementary and Integrative Medicine, 17(1). doi:10.1515/jcim-2018-0053 Meta-analysis / review
https://doi.org/10.1515/jcim-2018-0053 - Tha\c ci, S. and Krasniqi, B. and D\"ermaku-Sopjani, M. and Rifati-Nixha, A. and Abazi, S. and Sopjani, M (2022) 'Vasorelaxant effects of the Vitex agnus-castus extract', Evidence-Based Complementary and Alternative Medicine, 2022, pp. 7708781. doi:10.1155/2022/7708781 Preclinical
https://doi.org/10.1155/2022/7708781 - Puglia, L.T., Lowry, J. and Tamagno, G (2023) 'Vitex agnus castus effects on hyperprolactinaemia', Frontiers in Endocrinology. doi:10.3389/fendo.2023.1269781 Randomized trial
https://doi.org/10.3389/fendo.2023.1269781 - Zeqiri, A. and Dermaku-Sopjani, M. and Sopjani, M (2022) 'The mechanisms underlying the role of Vitex agnus-castus in mastalgia', Bratislava Medical Journal, 123(12), pp. 913--918. doi:10.4149/BLL_2022_147 Preclinical
https://doi.org/10.4149/BLL_2022_147 - Atmaca, M. and Kumru, S. and Tezcan, E (2003) 'Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder', Human Psychopharmacology, 18(3), pp. 191--195. doi:10.1002/hup.470 Randomized trial
https://doi.org/10.1002/hup.470 - Zamani, M. and Neghab, N. and Torabian, S (2012) 'Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome', Acta Medica Iranica, 50(2), pp. 101--106. Available at: https://pubmed.ncbi.nlm.nih.gov/22359078/ Randomized trial
https://pubmed.ncbi.nlm.nih.gov/22359078/ - Dugoua, J.-J. and Seely, D. and Perri, D. and Koren, G. and Mills, E (2008) 'Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation', Canadian Journal of Clinical Pharmacology, 15(1), pp. e74--e79. Available at: https://pubmed.ncbi.nlm.nih.gov/18204102/ Meta-analysis / review
https://pubmed.ncbi.nlm.nih.gov/18204102/
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.